Intas Pharma, Comera to develop bio-innovative biologic medicines

US-based Comera Life Sciences and

Indian firm Intas Pharmaceuticals have announced a research collaboration to develop a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. Under the terms of the agreement, Comera will develop a differentiated formulation of an Intas product using Comera’s innovative proprietary SQore formulation platform.

Intas will initially provide research funding with the option to acquire global rights to the formulation through an exclusive licence with responsibility for subsequent development and commercialisation. This collaboration will accelerate Intas’ quest to develop innovative, value-added medicines that can make a difference in patients’ lives globally.